Licensed by Pfizer Catalog No.S1408 Synonyms: PNU-100766
Molecular Weight(MW): 337.35
Linezolid is a synthetic antibiotic used for the treatment of serious infections.
Cited by 9 Publications
4 Customer Reviews
Auranofin inhibits MRSA toxin production and effectively clears intracellular bacteria. (a) Toxin production (ng/ml) in S. aureus MRSA USA300 after treatment with auranofin or control antibiotics (linezolid or vancomycin) for one hour (data corrected for organism burden). The results are presented as mean ± SD (n = 3). Statistical analysis was done by two-tailed Student’s ‘t’ test. Asterisks (**) indicate statistical significance in relation to the control (DMSO or water). P values of (**P ≤ 0.01) are considered significant. Detailed “P” values are listed below. α-hemolysin: control vs linezolid: 0.0027, control vs auranofin: 0.001. Panton-Valentine leukocidin: control vs linezolid: 0.0017, control vs auranofin: 0.0040. (b) MRSA USA300 infected J774A.1 cells were treated with auranofin and control antibiotics (vancomycin or linezolid) for 24 hours and the percent bacterial reduction was calculated compared to untreated control groups. The results are given as mean ± SD (n = 3). Two-tailed Student’s ‘t’ test was employed and P values of (*,# ≤ 0.05) are deemed significant. Auranofin was compared to controls (*) and to antibiotics (#). Detailed “P” values are listed below. Control vs linezolid: 0.0234, control vs vancomycin: 0.021, control vs auranofin: 0.02031, linezolid vs auranofin: 0.0397, vancomycin vs auranofin: 0.0491.
Sci Rep, 2016, 6:22571. Linezolid purchased from Selleck.
Efficacy of treatment of meticillin-resistant Staphylococcus aureus (MRSA) murine skin lesions with auranofin 0.5%, 1% and 2%, linezolid and clindamycin (25 mg/kg), mupirocin (2%), fusidic acid (2%) and petroleum jelly (control). Statistical analysis was performed by the two-tailed Student's t-test. *,# P-values of ≤0.05 were considered significant; auranofin was compared both with controls (*) and with antibiotics (#).
Int J Antimicrob Agents, 2016, 47(3):195-201. Linezolid purchased from Selleck.
Purity & Quality Control
Choose Selective Anti-infection Inhibitors
|Description||Linezolid is a synthetic antibiotic used for the treatment of serious infections.|
Linezolid inhibits initiation complex formation with either the 30S or the 70S ribosomal subunits from Escherichia coli. Linezolid inhibits complex formation with Staphylococcus aureus 70S tight-couple ribosomes.  Linezolid is a potent inhibitor of cell-free transcription-translation in E. coli, exhibiting 50% inhibitory concentrations (IC50s) of 1.8 mM.  Linezolid is an oxazolidinone, a new class of antibacterial agents with enhanced activity against pathogens.  Linezolid MICs vary slightly with the test method, laboratory, and significance attributed to thin hazes of bacterial survival, but all workers find that the susceptibility distributions are narrow and unimodal, with MIC values between 0.5 and 4 mg/L for streptococci, enterococci and staphylococci. Linezolid entails mutation of the 23S rRNA that forms the binding site.  Linezolid is an oxazolidinone whose mechanism of action involves inhibition of protein synthesis at a very early stage. Linezolid is added to 7H10 agar medium (Difco) supplemented with OADC (oleic acid, albumin, dextrose, and catalase) at 50°C to 56°C by doubling the dilutions to yield a final concentration of 0.125 μg/mL to 4 μg/mL. Linezolid shows excellent in vitro activity against all the strains tested (MICs ≤ 1 μg/ml), including those resistant to SIRE. 
-  Swaney SM, et al. Antimicrob Agents Chemother, 1998, 42(12), 3251-3255.
-  Shinabarger DL, et al. Antimicrob Agents Chemother, 1997, 41(10), 2132-2136.
-  Noskin GA, et al. Antimicrob Agents Chemother, 1999, 43(8), 2059-2062.
|In vitro||DMSO||67 mg/mL (198.6 mM)|
|Ethanol||8 mg/mL (23.71 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03583333||Recruiting||Hospital-Acquired Bacterial Pneumonia|Ventilator-Associated Bacterial Pneumonia||Merck Sharp & Dohme Corp.||September 18 2018||Phase 3|
|NCT03537495||Not yet recruiting||Tuberculosis Meningeal|Linezolid||Universitas Padjadjaran|Radboud University|Global Alliance for TB Drug Development||August 2018||Phase 2|
|NCT03474198||Recruiting||Tuberculosis Pulmonary||University College London|National University Hospital Singapore|Singapore Clinical Research Institute (SCRI)||March 21 2018||Phase 2|Phase 3|
|NCT03012360||Recruiting||Mechanical Ventilation Complication|Critical Illness||University Hospital Lille|Ministry of Health France||February 8 2018||Phase 4|
|NCT03086486||Recruiting||Tuberculosis Pulmonary|Tuberculosis Multidrug-Resistant|Tuberculosis MDR|Tuberculosis|Extensively Drug-Resistant Tuberculosis|Pre-XDR-TB||Global Alliance for TB Drug Development||November 21 2017||Phase 3|
|NCT03032380||Recruiting||Healthcare-associated Pneumonia (HCAP)|Hospital Acquired Pneumonia (HAP)|Ventilator Associated Pneumonia (VAP)||Shionogi|Shionogi Inc.||October 24 2017||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.